Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 13, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 680,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,466.5358 pence per share.
- Treasury Holdings Post-Transaction: 172,226,678 shares.
- Shares in Issue (excluding Treasury): 5,810,278,166 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 680,000 shares on June 13, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 680,000 share repurchase based on the disclosed price of 1,466.5358 pence.
- Confirm the updated total share capital structure (5,810,278,166 shares in issue plus 172,226,678 treasury shares).
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.